AllDocs -> cancers

Roy Castle Lung Cancer Foundation Ceridian proves “cost-effective solution” for Liverpool-based cancer charity. The Roy Castle Lung Cancer Foundation is the only charity in the World dedicated to defeating lung cancer , by promoting intensive research into its causes and prevention. They also offer advice to patients and their families on how best to manage it. Founded in 1990 by Ray Donnelly, a leading authority on lung cancer , it was originally called The Lung Cancer Fund before taking the name of the late TV presenter – who dedicated the last year of his life to supporting the Foundation’s work. Today the charity lists many other celebrities among its patrons, including Sir Cliff Richard (Life President) and actress Dame Judi Dench. Funded by donations from the public and local businesses, the Foundation has built The Roy Castle International Centre for Lung Cancer ...

Incidence and mortality In 2001 22,700 men and 14,700 women were diagnosed with lung cancer in the UK. 1 In 2003 19,800 men and 13, 600 women died from lung cancer in the UK. 2 Background x Most common cancer in men and women in UK and USA x 80% are the result of smoking x Small cell lung cancers (SCLC) comprise 25% x Non-small cell lung cancers (NSCLC) comprise the remaining 75% • Squamous cell carcinoma 30% • Adenocarcinoma (including bronchioalveolar carcinoma) 35% • Large cell anaplastic carcinoma 10% Natural history x The pattern of growth is related to cell histology • Adenocarcinomas grow slowly • Small cell carcinoma metastasizes early with 80–90% having spread beyond the thorax at the ...

The Australian Lung Foundation / Lung Cancer Consultative Group Undergraduate Cochrane Review Scholarship These scholarships are valued at $1,500 and are specifically designed to assist a medical undergraduate in undertaking a research project into lung cancer . A scholarship of up to $1,500 each will be offered to two undergraduates in 2006 to study Evidence-Based Medicine. This ALF award is aimed at providing a systematic and up-to-date summary of reliable evidence of the benefits and risks of healthcare for lung cancer . It is envisaged that the project would be conducted during a designated undergraduate research elective period (or equivalent) or possibly as a component of a Bachelor of Medical Science degree. The Scholarships will be awarded for the purpose of undertaking a Cochrane Systematic Review of the Lung Cancer Group, and may be undertaken in conjunction with ...

Bounding analysis of lung cancer risk using imprecise probabilities Minh Ha-Duong 1 , Elizabeth Casman 2 and Granger Morgan 2 1 CNRS, France 2 Carnegie Mellon University, USA Bounding analysis of lung cancer risk using imprecise probabilities – p.1/10 Page 2 Authors’ research interests Granger M. Morgan, Lord Chair Professor and Department Head: Public policy; risk analysis; expert elicitation. Elizabeth Casman, Research Engineer: Epidemiology, malaria, security. Minh Ha-Duong, Chargé de Recherche, visiting: Uncertainty, environmental economics, global change, integrated assessment models. Bounding analysis of lung cancer risk using imprecise probabilities – p.2/10 Page 3 Lung cancer ...

Statistics Courtesy of the Lung Cancer Alliance Nearly one in every three cancer deaths is due to lung cancer . Lung cancer kills: An average of 440 people a day, one every three minutes. More than breast, prostate, colon, kidney, melanoma and liver cancers combined. Three times as many men as prostate cancer and twice as many women as breast cancer . More women than breast, cervical and ovarian cancers combined. Non-smokers and former smokers now account for more than 60 percent of new lung cancer cases, a fact that the public is just starting to become aware of. 50 percent of new cases in former smokers: Tong L, Spitz MR, Fueger JJ, et al: “ Lung Carcinoma in Former Smokers.” Cancer 78:1004-10, 1996. Warner EE, Mulshine JL, “ Lung Cancer Screening With Spiral CT: Toward a Working Strategy.”Oncology (Williston Park). 2004 May; 18(5):564-75, ...

Purpose Define the anatomical location and relationship of the tumor to other structures in order to plan therapy. Calculate the volume of the tumor before and after therapy to assess response. Methods Gadolinium enhanced MRI was performed pre- and post- therapy. Barco’s volume-rendering software on a PC-based platform was used for 3D image post-processing. 3D processing was performed on the original MRI to plan therapy while volume measurements were performed on the pre- and post- therapy images to assess tumor response to therapy. 3D color volumes were generated from the coronal gadolinium- enhanced SGE MRI images. Case: Pre and postchemotherapy assessment of lung cancer Presented by Russell N. Low, M.D., Medical Director, Sharp and Children’s MRI Center, San Diego, CA Onc ology The field of view was reduced to the volume of interest around ...

Burden of lung cancer due to occupational carcinogen exposure in South Africa, 2000 Pam Groenewald Objectives To estimate the fraction of lung cancer attributable to current or past exposure to occupational carcinogens in South Africa in 2000. Methods The estimation of the burden of lung cancer attributable to current or past exposure to occupational carcinogens for South Africa, 2000, followed the methods used by WHO for assessing the global burden of disease from occupational exposure to carcinogens 1 . We followed the steps outlined in one of the Environmental Burden of Disease series published by the WHO, which provides a more detailed step-by- step explanation of the methods for assessing the environmental burden of disease at national level 2 . The following steps are required: 1. Identify known occupational lung carcinogens ...

Heine H Hansen, MD, is Professor (Personal Chair) of Clinical Oncology at the University of Copenhagen (UoC), Denmark. His previous posts include Assistant Professor of Internal Medicine, George Washington University, US, and Senior Lecturer, Internal Medicine, UoC. Dr Hansen is the Editor of several Danish and international textbooks and, since 1985, Editor- in-Chief of the journal Lung Cancer . He has also published more than 300 articles in international journals on basal and clinical aspects of cancer , with special emphasis on lung cancer and other solid tumours, and on the development of new anti- cancer agents. He is Past Chairman of the Danish Society for Cancer Research and the Danish Society for Medical Oncology, and Past President of the International Association for the Study of Lung Cancer (IASLC) and the European Society ...

Lung cancer gene has gender bias Of all cancers, lung cancer causes the most deaths in the United States. Smoking leads to almost 90 percent of cases, but researchers have been unable to explain why among smokers, women seem to be 2 to 3 times as susceptible to the disease as men are. A new study may help explain this gender bender. A gene for a protein that promotes lung cancer growth is more likely to be active in women than in men, says Sharon P. Shriver of Pennsylvania State University in State College. Known as gastrin-releasing peptide receptor, or GRPR , the gene is not typically active in the lungs of nonsmokers, Shriver says. Tests of lung cancer cells, however, show that nicotine turns the gene on, she and her colleagues at the University of Pittsburgh report in the Jan. 5 J OURNAL OF THE N ATIONAL C ANCER I NSTITUTE . ...

ISSUE 19 • SUMMER 2006 HEALTH NEWS FOR RESPIRATORY PATIENTS AND THEIR FAMILIES When it comes to lung cancer , secondhand smoke is definitely mainstream — a major cause of the disease in non-smokers. Heather Crowe, who died of lung cancer in May was a cross-Canada icon for the issue. A lifelong non-smoker, Crowe worked for 40 years as a server in smoke-filled Ottawa-area restaurants, but became a public person only after her 2002 diagnosis. It led to: • A successful fight for Canada’s first full workers’ compensation benefits for lung cancer from workplace exposure to secondhand smoke. • Television stardom in a national Health Canada campaign on secondhand smoke. • Public education appearances in all parts of the country to meet politicians and community and school groups. Radiation therapy and a 75-per-cent loss of lung function ...

CIK 8852 CENTER FOR CONTINUING EDUCA TION 986800 Nebraska Medical Center Omaha, NE 68198-6800 NONPROFIT ORG. U.S. POST AGE P A I D OMAHA, NE PERMIT NO. 454 FALL MIDWEST LUNG CANCER CONFERENCE FALL MIDWEST LUNG CANCER CONFERENCE September 15-16, 2006 Omaha Marriott Hotel 10220 Regency Circle Omaha, Nebraska FRIDAY, September 15, 2006 7:30 a.m. R EGISTRATION AND C ONTINENTAL B REAKFAST 8:00 a.m. W ELCOME /I NTRODUCTIONS Rudy P. Lackner, MD 8:10 a.m. P ATHOLOGY OF L UNG C ANCER William W. West, MD 8:50 a.m. L UNG C ANCER S CREENING ...

4 | Visit our Web site at www.evergreenhealthcare.org Visit our Web site at www.evergreenhealthcare.org | 5 Lung Cancer Lung cancer is a particularly nasty opponent. Due in large part to late detection, the survival rate for patients is only about 12 percent. WarnInG sIGns Lung cancer often does not cause symptoms for many years. As a result, lung cancer is frequently discovered only when physicians are screening patients for other conditions. Symptoms may include: • A persistent cough • Chest pain • Hoarseness • Weight loss and loss of appetite • Spit or phlegm that is bloody or rust-colored • Shortness of breath • Repeated bouts of pneumonia or bronchitis If you have any of these symptoms, talk to a doctor immediately. rIsK faCTors • Ninety percent of lung cancers occur in people who smoke. The more ...

- 1 - Registered in England & Wales No. 3888792 Registered Office 980 Great West Road Brentford, Middlesex, TW8 9 This press release is intended for medical and financial media representatives. E NCOURAGING R ESULTS OF A C LINICAL S TUDY W ITH GSK’S N OVEL C ANCER I MMUNOTHERAPY R EPORT A CTIVITY IN P ATIENTS WITH M OST C OMMON F ORM OF L UNG C ANCER F IRST DATA FROM A PHASE II CLINICAL TRIAL EVALUATING GSK’ S MAGE-A3 CANCER IMMUNOTHERAPY GlaxoSmithKline (NYSE and LSE: GSK) today announced that interim ...

M K T 0 5 - C N R - 0 3 5 Lung Cancer Clinic Team-based assessment, management and second opinion service Taussig Cancer Center Dear Colleague: The Cleveland Clinic Taussig Cancer Center recently expanded services for people with lung cancer . Within the new Lung Cancer Clinic, patients have access to specialized services for the evaluation and management of lung cancer and lung nodules, as well as second opinions, and cancer pain treatment. Through a team-based assessment and management approach, we can offer the latest therapies, reduce treatment complications and enhance overall quality of life. Same-day assessments are provided by physicians from a range of disciplines, including Medical Oncology, Pulmonary Medicine, Thoracic Surgery, Radiation Oncology, Pain Management, Palliative Medicine, Radiology ...

W EDNESDAY , S EPTEMBER 6 TH 2006 421. Genetics in lung cancer E4680 Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Nadejda V. Cherdyntseva 1 , Valentina A. Belyavskaya 2 , Polina A. Gervas 1 , Maria V. Fleming 1 , Natalia V. Sevostyanova 3 , Sergei A. Kolomyiets 3 , Mikhail I. Voevoda 2 . 1 Immunology Dpt, Cancer Res Inst of RAMS, Tomsk, Tomsk Obl, Russia; 2 Virology Dpt, State Scientific Centre of Virology and Biotechnology, Novosibirsk, Novosibirsk Obl, Russia; 3 Thoracic Oncology Dpt, Regional Oncology Clinic, Tomsk, ...

T UESDAY , S EPTEMBER 5 TH 2006 395. Lung perfusion and lung cancer : imaging, diagnosis and treatment E4439 Degree of concordance between spiral computed tomography and ventilation perfusion lung scan in the diagnosis of pulmonary thromboembolism Margarida Palla Garcia 1 , Filipa Todo Bom 1 , Ana Cristina Mendes 1 , Wilma Magalhães 1 , Guilhermina Cantinho 2 , Paula Campos 3 , Isabel Correia 1 , Renato Sotto Mayor 1 , António Bugalho de Almeida 1 . 1 Pneumology Department, Hospital de Santa Maria, Lisboa, Portugal; 2 Nuclear Medicine Department, Faculdade de Medicina de Lisboa, Lisboa, Portugal; 3 Radiology Department, ...

Lung Cancer and Mesothelioma During Prospective Surveillance of 1249 Asbestos Insulation Workers, 1963-1974* Irving J. Selikoff Environmental Sciences Laboratory Mount Sinai School of Medicine The City University of New York New York, New York 10029 INTRODUCTION In 1963, it was found that a large group of asbestos insulation workers in the New York metropolitan area had experienced unusual mortality during 1943-1962. 1 Six hundred and thirty-two men had been on the union's rolls on January 1, 1943. By December 31, 1962, 262 men had died, nine before reaching 20 years on the job. Of those who died after 20 years from first employment, lung cancer was found in marked excess; 6.02 such deaths had been expected, and 42 occurred. In addition, there were several deaths due to pleural or peritoneal mesothelioma and a modest increase in deaths due to, gastrointestinal ...

E-P OSTERS IN F REE A CCESS 31. Lung cancer , haemoptoe, smoking and COPD E340 Treatment success and survey in pleurodesis cases Ufuk Memis 1 , Gulfer Okumus 1 , Esen Kiyan 1 , Ziya Gulbaran 1 , Halim Issever 2 , Orhan Arseven 1 . 1 Pulmonary Medicine, Istanbul Medical Faculty, Istanbul, Turkey; 2 Public Health, Istanbul Medical Faculty, Istanbul, Turkey Background: Pleurodesis is a procedure designed for the symptomatic treatment for recurrent pneumothorax, malign and benign effusions. Sclerosing agents are 39s Abstract printing supported by Nonin Medical, Inc. Visit Nonin Medical, Inc. at stand C09 Page 2 E-P OSTERS IN F REE ...

Lung Cancer a report by Rober t James Cerfolio , MD , FACS , FCCP Professor of Surgery, Chief of Thoracic Surgery, Division of Cardiothoracic Surgery, University of Alabama at Birmingham Although smoking rates have declined in the US, lung cancer , also called bronchogenic malignancy continues to represent a pandemic. It is the number one cause of cancer related deaths worldwide,as well as in the US.In 2003 there were 171,900 patients diagnosed with lung cancer and 157,200 people died from it in the US alone in that year.The number of deaths from lung cancer in the US is equivalent to a jumbo jet airplane filled to capacity crashing, every day, day after day with no survivors. Over 80% of bronchogenic malignancy is from non-small cell lung cancer (NSCLC) and thus is the main focus of this report. Despite significant advances, the overall ...

J R Coll Physicians Edinb 2006; 36: 000–000 © 2006 RCPE CME PN J R Coll Physicians Edinb 2006; 36: 000–000 © 2006 Royal College of Physicians of Edinburgh SESSION 1 THE SCALE OF THE PROBLEM – AND CAN THAT BE CHANGED? Dr D Brewster, Professor H Burns, Professor J Jett At present, there are more than 4,000 new cases of lung cancer and just fewer than 4,000 deaths from lung cancer reported per year in Scotland. However, there does appear to be a decrease in incidence of lung cancer among the male population, and a levelling off in the female population. There is evidence that smoking cessation leads to a substantial and significant reduction in lung cancer risk with 30 years of abstinence leading to a relative risk reduction of 90%. 1 Since it has been shown that 60–70% of smokers want to stop,the emphasis must ...

Chairmen Dr. Manuel Dómine Fundación Jiménez Díaz, Madrid Dra. Pilar Garrido Hospital Ramón y Cajal, Madrid Dr. Rafael Rosell ICO, Hospital Germans Trias i Pujol, Barcelona MADRID 16 th and 17 th of NOVEMBER, 2006 Plenary Session & III Educational Symposium of the Spanish Lung Cancer Group MADRID 16th and 17th of NOVEMBER, 2006 Registration Accommodation Form & Plenary Session & III Educational Symposium of the Spanish Lung Cancer Group Under the auspices of Venue All sessions will take place at the: Gran Anfiteatro Colegio Oficial de Médicos de Madrid C/ Santa Isabel, 51 - 28012 Madrid (Spain) Language Sessions will be in English or Spanish. Credits Request to be declared of Scientific Health Interest presented ...

Lung Cancer Treatment Update Presented by Richard J. Gralla, MD New York Lung Cancer Alliance Winfield A. Boerckel, MSW, MBA Cancer Care Find out about: • Lung cancer basics • Diagnostic tools • Treatment options • Your support team Help and Hope LUNG CANCER Page 2 National Office Cancer Care 275 Seventh Avenue New York, NY 10001 Email: teled@cancercare.org Services Tel: 212-712-8080 1-800-813-HOPE (4673) Administration Tel: 212-712-8400 Fax: 212-712-8495 Email: info@cancercare.org Website: www.cancercare.org Cancer Care is a national nonprofit organization that provides free professional support services to anyone affected by cancer : people with cancer , caregivers, children, loved ones, and the bereaved. Cancer Care programs ...

Thomas G. Labrecque Foundation (212) 651–6420 www.tglfoundation.com 1 $23,474.00 $14,369.00 $5,216.00 $1,829.00 $- $5,000.00 $10,000.00 $15,000.00 $20,000.00 $25,000.00 Breast Prostate Colon Lung Total Research Spending Per Death 2005 ($) Breast Prostate Colon Lung Committed to preventing lung cancer through education and research. May 15, 2006 VOLUME 1, NUMBER 1 We hope you enjoy the first issue of our bi-annual newsletter. Get in-depth information on the latest Foundation and ‘Run as One’ event updates. Update It’s been an exciting four years for the Thomas G. Labrecque Foundation Thanks to our generous sponsors and donors, over $2.5 million has been raised for lung cancer research since the Foundation’s inception in 2003. Funding has been donated to the Thomas ...

501 Elliott Ave. W. #400 Seattle, WA 98119 T 206.282.7100 F 206.272.4010 New Poll Shows Women Unaware of the Rise and Dangers of Lung Cancer Study released in advance of National Women’s Health Week (May 14 – 20) May 10, 2006 Seattle —A new national poll shows that American women show little concern about developing lung cancer , despite the fact that it is the number one cancer killer of women. Lung cancer will kill more than 70,000 women this year — more than breast cancer (approximately 41,000) and ovarian cancer (approximately 15,000) combined. Lung cancer death rates for U.S. women are among the highest in the world. The poll was commissioned by Cell Therapeutics, Inc. (CTI) (NASDAQ and MTAX: CTIC). During the past 20 years, lung cancer deaths among women increased nearly 200 percent, while the number for men decreased about 5 percent. Yet women are even ...

Lung cancer is the number one cause of cancer mortality. Although this malignancy is potentially curable if diagnosed and treated in the early stages, the majority of patients are diagnosed in the advanced stages precluding consideration of therapy for cure or long term disease control. There are no formal screening programs to detect lung cancer in its early stages. However, it is clear that the best (indeed only) chance of cure is detection at the earliest possible stage . There is data to suggest that even after the diagnosis is made during the period of waiting for therapy, significant growth of malignancy occurs as measured radiologically. 1 In lung cancer , advanced stage correlates with worse survival (five year survival rate for Stage Ia is 61% versus 24%for IIb, 13% for IIIa, 5% for IIIb and 1% for IV). This data illustrates the potential impact of the current wait times that patients ...

Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill Page 2 Lung Cancer A Public Health Problem • In 2006 – 168,000 cases – 156,000 deaths • Symptomatic disease associated with >90% mortality • Chest X-ray: leading detection tool but >67% of new cases already advanced • Median survival of metastatic disease is about 1 year • Average loss of life: 14.7 years Page 3 Lung Cancer in the U.S. in 2005: Incidence and Mortality 1 New cases: 172,570 Rank 93,010 males #2 79,560 females #2 Annual deaths: 163,510 90,490 ...

888 16th Street NW Suite 800 Washington DC 20006 202-463-2080 lungcanceralliance.org NO MORE EXCUSES. NO MORE LUNG CANCER . If you think lung cancer just affects men, think again. Lung cancer is now the number one killer of women, claiming the lives of more women each year than breast cancer . Lung cancer is not declining among women, as it is among men. One in every 17 women will develop lung cancer in their lifetimes. It is estimated that over 80,000 women will get lung cancer this year— nearly half of all lung cancer cases. An estimated 72,000 American women will die from lung cancer this year, making up over 40 percent of all lung cancer deaths in this country. In one study, women with a long smoking history were nearly twice as likely to be ...

888 16th Street NW Suite 800 Washington DC 20006 202-463-2080 800-298-2436 hotline lungcanceralliance.org NO MORE EXCUSES. NO MORE LUNG CANCER . About Lung Cancer Alliance Lung Cancer Alliance is the only national non-profit organization providing patient support and advocacy exclusive to those living with or at risk for lung cancer . Headquartered in Washington, DC, Lung Cancer Alliance is committed to making lung cancer a national public health priority. Our Goal To eradicate lung cancer . Our Commitments We are committed to the following actions and initiatives: Advocacy • Elevate lung cancer to a national public health priority. • Educate federal/state policy leaders of the need for greater resources for lung cancer research for prevention, early detection, and treatment. ...

888 16th Street NW Suite 800 Washington DC 20006 202-463-2080 lungcanceralliance.org NO MORE EXCUSES. NO MORE LUNG CANCER . Board of Directors Interim Chairman of the Board J. Steven Hart President & CEO of Williams & Jensen Washington, DC Paul A. Bunn, Jr., MD Professor of Medicine and Director of University of Colorado Cancer Center Denver, CO James L. Mulshine, MD Associate Provost for Research and Vice President for Research, Rush Medical School Chicago, IL Priscilla Dewey Houghton Arts Advocate Cohasset, MA Cheryl Healton, Dr. PH President & CEO of American Legacy Foundation Washington, DC Harvey I. Pass, MD Professor and Chief for Division of Thoracic Surgery and Oncology NYU School of Medicine and Comprehensive Cancer ...

Clinical Focus on Lung Cancer A snapshot of lung cancer for Ontario health care providers and managers Driving quality, accountability and innovation throughout Ontario’s cancer system Page 2 C LINICAL F OCUS ON L UNG C ANCER Prepared by: Dr.W.K.(Bill) Evans Chief Medical Officer and Provincial Vice-President Cancer Care Ontario and Chair, Lung Disease Site Group With the Assistance of: Dr.Terrence Sullivan Deborah Fitzsimmons Dr.Eric Holowaty Alex Drossos Dr.Anthony Whitton Mark Gregus Dr.Brent Zanke Diane Nishri Dr.Loraine D.Marrett Saira Bahl Ian Brunskill Sherman Quan Beth Theis Bev Hess May 2004 T ABLE OF C ONTENTS ...